The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
about
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionEfficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma.Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsEfficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience.Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewImpact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesTargeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus.Current status of targeted therapy for advanced renal cell carcinomaAntiangiogenic therapy: impact on invasion, disease progression, and metastasis.A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinomaEvaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Sunitinib treatment for metastatic renal cell carcinoma in patients with von hippel-lindau disease.Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.Treatment of metastatic renal cell carcinoma and renal pelvic cancer.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Axitinib plasma pharmacokinetics and ethnic differences.Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational studyReal-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib.Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
P2860
Q26852437-4D3C85CE-7B38-4DAB-9515-F546BFB1F79FQ28550377-61078DE9-6867-478C-96F9-19214A8595F2Q33399152-0B5AA5DF-E855-45C5-9716-21A52FF8A557Q33413566-EB268719-FFB2-424F-8CAB-97215A727FD2Q33422376-68EBC5BD-DB52-4068-93C4-935941A0078AQ33437427-A1BEF45F-F63D-4C0B-BC1E-A221D18FB16CQ33440354-85EBC0CE-7D16-4943-A9A1-1FB42BA1C97EQ33633431-E2B588D9-46A5-4029-BF49-6765F0B08811Q33698419-F6A29C73-5945-4B09-9FBE-216784CFCC90Q34009449-C1C0EA8B-6089-43D7-A9DC-7A6EC67C7B3BQ34657590-8B1919FC-FBB6-4BB3-B43A-2C2F57C37BBCQ34982554-A9DF2CC2-5CC4-4B80-99C9-8C47C1FE50EDQ35063752-4A65FDCF-CE46-461A-BD4A-691BF03E2BABQ35903850-70564060-4095-4560-BC37-719B02D8302EQ35966757-240388D1-BEE7-4160-A4BA-C987A78A30F9Q36093104-0838AAA8-B508-4857-BF45-42F03C0CB3DEQ36907986-6255FCE9-E55C-4D50-A79B-D1467865D2E6Q37387563-61BC2B7D-B8D8-40DB-8BDD-0790F5874FEDQ37484608-C3C8E6BA-B95F-4094-87C0-2C181A4AA29AQ37650644-36197ACD-6083-4490-B5E1-C2CE9337F974Q37863582-76F4A37B-F185-4B12-B89D-2C798B11BF39Q38004605-E2BF7774-CA1A-40FF-99A3-8527D74C9FB7Q38076349-0F3674D7-BAFE-4749-BE77-FE2D9C675DAEQ38348548-8F7018D4-C0F0-40B9-ACD9-10CC40B8F286Q38531928-06817233-FA7C-409B-85C4-C373A9127581Q38749318-0FA41D94-DB44-4996-ADAE-1E05809007F3Q39048761-6CBB1FC3-CB9B-40EF-9ECC-198B12EE3D7AQ39065451-AC048406-74D0-4833-9608-1ADD551EB2B8Q39348852-D980D005-208D-49F2-A30F-E69E46DF2AF3Q40189187-5357ADCF-2922-4AFA-B26B-88AB0A13D9A0Q43725656-29A37F8A-8365-417F-BE41-4E4CD21E1EF4Q45082802-78B862E2-C190-4ED6-8BCD-95CA386CD1D8Q45093247-B7DA9818-4F46-4C02-A293-05F69DFA3EA4Q50529718-AD30D3AA-C27F-48E5-A29B-13DDABDC65AAQ50600192-9E73D92C-BD7B-4441-BE56-265A12E8601FQ50968798-6AF27C63-556D-4754-85AB-CB7F867F0C57Q53197402-E1F20175-DAEC-461B-B999-87A37AAE02D7Q53581485-0FE77829-4D3A-4A09-8F45-AC3962CCD895Q53669584-BB08DAB1-0F85-4710-A29A-3B62C10122A4Q55021037-749B336C-6FE5-4411-9D19-167F2B2D7B35
P2860
The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The efficacy and safety of sun ...... ds to frequent dose reduction.
@ast
The efficacy and safety of sun ...... ds to frequent dose reduction.
@en
type
label
The efficacy and safety of sun ...... ds to frequent dose reduction.
@ast
The efficacy and safety of sun ...... ds to frequent dose reduction.
@en
prefLabel
The efficacy and safety of sun ...... ds to frequent dose reduction.
@ast
The efficacy and safety of sun ...... ds to frequent dose reduction.
@en
P2093
P356
P1476
The efficacy and safety of sun ...... ds to frequent dose reduction.
@en
P2093
Bumsik Hong
Changhoon Yoo
Cheryn Song
Choung-Soo Kim
Dae Ho Lee
Hanjong Ahn
Jae-Lyun Lee
Jeong Eun Kim
Jin-Hee Ahn
Jun Hyuk Hong
P304
P356
10.1093/JJCO/HYQ073
P577
2010-05-10T00:00:00Z